Navigation Links
Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
Date:4/10/2013

phan and difficult-to-drug GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding its intellectual property position around the orphan GPCRs that it unlocks; the
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
2. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
3. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
4. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
5. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
6. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
7. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
11. Omeros is Not Aware of Any Justification for Share Price Movement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s ... about some of our Medicare resources and continue highlighting the success of the prescription ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... poultry ... processing plants., SHREVEPORT, La., Nov. ... poultry processing, was identified,in an October 2007 Watt Poultry USA article ... in large-scale processing plants, University of,Georgia Associate Professor of Poultry Science ...
... American Heart Association Scientific Sessions 2007 ... ... Nov. 6 ARCA Discovery, a privately held,biopharmaceutical company, announced today ... bucindolol, a,next-generation beta-blocker and vasodilator for heart failure, atrial,fibrillation, and arrhythmia, ...
Cached Medicine Technology:FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma' 2ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 2ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 3ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 4ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 5
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... ... , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection ... exam easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published ... if they could reach a consensus on the steps that need to be taken ... group reached 90 percent consensus on a series of steps that each surgeon must ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... educating both readers and potential patients alike on various plastic surgery procedures including, ... covered also include such popular dermatology procedures like Botox and fillers. , ...
(Date:7/31/2015)... ... , ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue ... for the first six months ended June 30, 2015 compared with the same period ... year’s record-revenue mark of $10.4 million. , “We know what our customers need and ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2
... to create better value, lower transaction costs in healthcare ... advanced, high volume document and payment processing services and ... in an effort to improve health costs, quality and ... the 7th Annual Medical Banking Institute, to be held ...
... Hospira, Inc. (NYSE: HSP ), a leading ... that Heino von Prondzynski has been elected to the ... management and diverse global experience from leadership positions held ... expands Hospira,s board to 10 directors, of whom nine ...
... The BlueCross BlueShield of South Carolina Foundation will ... Partnership program in Horry County to support first time ... begin at noon, March 13, in Ballroom C of ... Myrtle Beach, S.C.The BlueCross Foundation is proud to partner ...
... Builds on Web based platform to provide additional ... CardioVascular, a FUJIFILM company, is pleased to announce ... Synapse(TM) ProSolv(R) cardiovascular 4.0.1. Key features of ... integration with the Siemens Sensis Hemodynamic system. ...
... may be ticking too, researchers say, , , MONDAY, March 9 ... till later in life may pay a price: slightly lowered ... Australian study that found that kids born to older men ... years of age, compared with children of younger fathers. , ...
... Information on Medicare Advantage Special Needs Plans, Tips ... 9 A series of free seminars designed ... maintain a healthy lifestyle and learn about Medicare ... needs will be offered during March at various ...
Cached Medicine News:Health News:BancTec Provides Thought Leadership at 7th Annual Medical Banking Institute 2Health News:BancTec Provides Thought Leadership at 7th Annual Medical Banking Institute 3Health News:Hospira Expands Board of Directors 2Health News:S.C. BlueCross Foundation to Grant More Than $1.3 Million to Support First Time Mothers in Horry County 2Health News:ProSolv Releases New Cardiovascular Software 2Health News:ProSolv Releases New Cardiovascular Software 3Health News:Late-Life Fatherhood May Lower Child's Intelligence 2Health News:Late-Life Fatherhood May Lower Child's Intelligence 3Health News:Free Seminars Offered to Texas Seniors with Diabetes and Other Chronic Illnesses 2
... Biotrace Sterile Barium Sulfate USP is ... and consistent imaging capabilities for todays ... via minimally invasive surgery. Comprised of ... an even diffusion of sterile barium, ...
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
... Bone Cement consists of a ... containing bone cement liquid within ... sterile polyethylene bag,containing bone cement ... The interiors of the blister ...
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
Medicine Products: